Long-term benzodiazepine and Z-drugs use in England: a survey of general practice
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: Current British National Formulary (BNF) guidelines state that benzodiazepines and zolpidem, zopiclone, and zaleplon, commonly known as Z-drugs (BZD), be prescribed for no more than 4 weeks, although anecdotal data suggest that many patients are prescribed BZDs for much longer. As there are no recent, evidence-based estimates of long-term (>12 months) BZD use in England, the scale of this potential problem is unknown. Aim: To produce the first reliable, evidence-based estimate of long-term BZD use in England. Design and setting: Estimates of long-term BZD use in England were projected from data obtained from a survey conducted in 2014–2015 by the Bridge Project, a prescribed-drug withdrawal support charity in the North of England (Bradford). Method: Percentages of long-term users of BZD were derived from the survey, by sampling primary care GP surgeries with around 100 000 registered patients, and these were applied to English NHS patient numbers. The data were filtered to exclude the very young and old, and those with other health issues. Results: The mean percentage of registered patients prescribed BZDs for more than a year in the survey sample is 0.69% (95% confidence interval [CI] = 0.54 to 0.84). Applying this value to national patient numbers yields a mean projection of 296 929 (95% CI = 232 553 to 361 305) long-term users of BZD in England. The data also suggest that as many as 119 165 of these patients may be willing to accept prescribed drug dependency withdrawal services. Conclusion: More than a quarter of a million people in England are likely to be taking highly dependency-forming hypnotic medication far beyond the recommended time scales. As there is evidence that long-term use of BZDs causes adverse physiological and neurological effects, and protracted withdrawal (with associated complications), this represents a serious public health problem.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cambridge Handbook of Psychology, Health and Medicine
(2001) · doi:10.1017/cbo9780511543579 · Cited by 393
Benzodiazepine withdrawal: outcome in 50 patients
ASHTON, H. (1987) · British Journal of Addiction · doi:10.1111/j.1360-0443.1987.tb01529.x · Cited by 160
Nielsen, M., Hansen, E. H., & Gøtzsche, P. C. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03686.x · Cited by 103
Cited by
Cryo-EM: the resolution revolution and drug discovery
de Oliveira, T. M., van Beek, L., Shilliday, F., Debreczeni, J. É., & Phillips, C. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220960401 · Cited by 73
Takaesu, Y., Utsumi, T., Okajima, I., Shimura, A., Kotorii, N., Kuriyama, K., Yamashita, H., Suzuki, M., Watanabe, N., & Mishima, K. (2019) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2019.101214 · Cited by 57
Soni, A., Thiyagarajan, A., & Reeve, J. (2023) · Addiction · doi:10.1111/add.15997 · Cited by 41
Pharmacological principles for safe benzodiazepine and Z-drug dose reduction
Horowitz, M., Lamberson, N., Brandt, J., Framer, A., Shapiro, B., Sørensen, A., Cadogan, C., Ritvo, A., & Taylor, D. (2026) · Psychological Medicine · doi:10.1017/s0033291726104887
Metadata
- Authors
- Davies, J., Rae, T. C., & Montagu, L.
- Venue
- British Journal of General Practice
- Published
- 2017-07-17
- Volume
- 67
- Issue
- 662
- Pages
- e609-e613
- ISSN
- 0960-1643 (ISSN-L)
- 1478-5242
- OpenAlex
- W2734711267
- Cited by
- 99
- References
- 3
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term benzodiazepine and Z-drugs use in England: a survey of general practice. https://app.cochat.ai/papers/10.3399/bjgp17x691865
- The paper
- Davies, J., Rae, T. C., & Montagu, L. (2017). Long-term benzodiazepine and Z-drugs use in England: a survey of general practice. British Journal of General Practice. https://doi.org/10.3399/bjgp17x691865
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.